The new immunosuppressive malononitrilamide MNA 279 prolongs skin xenograft survival in a mouse-to-rat model.
Schorlemmer
H U
HU
Research Laboratories of Hoechst Marion Roussel (HMR), DG-Rheumatology/Immunology, Behringwerke AG, Marburg, Germany.
Kurrle
R
R
D000818:Animals; D000910:Antibodies, Heterophile / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D009570:Nitriles / Q000627:therapeutic use*; D051381:Rats; D011917:Rats, Inbred Lew; D016038:Skin Transplantation / Q000276:immunology*; D014183:Transplantation, Heterologous / Q000276:immunology*
D000910:Antibodies, Heterophile; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D009570:Nitriles; C102911:X 910279; D016572:Cyclosporine